Literature DB >> 11735170

Micrometastases in bone marrow of patients with suspected pancreatic and ampullary cancer.

N T van Heek1, M Tascilar, J L van Beekveld, P Drillenburg, G J Offerhaus, D J Gouma.   

Abstract

AIMS: This prospective study aimed to evaluate the detection of micrometastases in bone marrow of patients with suspected pancreatic and ampullary cancer and to determine their predictive value on overall survival.
METHODS: Between December 1997 and December 1998, 35 patients (19 male, 42-77 years) with suspected pancreatic and ampullary cancer underwent diagnostic laparoscopy as a final staging procedure before exploration. Bone marrow was aspirated from the iliac crest at the beginning of laparoscopy. Mononuclear cells were isolated and stained using the specific monoclonal antibody CAM 5.2.
RESULTS: Cytokeratin-positive cells were detected in 12/35 (34%) of all patients. In the 31 patients with a final diagnosis of carcinoma, a positive staining was found in 10/31 (32%) of the bone marrow aspirates. After a median follow-up of 17 months (2-24), 15/31 (48%) patients had died: 7/10 (70%) with and 8/21 (38%) without micrometastases (* P<0.04). All four patients who turned out to have chronic pancreatitis were alive without malignancy. In two of these four patients, distinct cytokeratin-positive cells were seen.
CONCLUSIONS: Micrometastases in bone marrow of patients with the final diagnosis pancreatic or ampullary carcinoma seem to predict a significantly shorter survival. However, clinical use of cytokeratin markers cannot be recommended at present, because false-positive staining was found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735170     DOI: 10.1053/ejso.2001.1209

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients.

Authors:  Katrin Hoffmann; Christiane Kerner; Wolfgang Wilfert; Marc Mueller; Joachim Thiery; Johann Hauss; Helmut Witzigmann
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

2.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival.

Authors:  Edlyn Soeth; Urte Grigoleit; Barbara Moellmann; Christian Röder; Bodo Schniewind; Bernd Kremer; Holger Kalthoff; Ilka Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-01       Impact factor: 4.553

3.  Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance.

Authors:  Peter Scheunemann; Nikolas H Stoecklein; Kai Hermann; Alexander Rehders; Claus F Eisenberger; Wolfram T Knoefel; Stefan B Hosch
Journal:  Langenbecks Arch Surg       Date:  2008-07-15       Impact factor: 3.445

4.  Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma.

Authors:  R Andersson; C E Vagianos; R C N Williamson
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

Review 5.  The effects of staging laparoscopy on trocar site and peritoneal recurrence of pancreatic cancer.

Authors:  V Velanovich
Journal:  Surg Endosc       Date:  2003-12-29       Impact factor: 4.584

6.  Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis.

Authors:  David Stephenson; Christopher Nahm; Terence Chua; Anthony Gill; Anubhav Mittal; Philip de Reuver; Jaswinder Samra
Journal:  Oncotarget       Date:  2017-08-04

7.  Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information.

Authors:  Harald Hugenschmidt; Knut Jørgen Labori; Cathrine Brunborg; Caroline Sophie Verbeke; Lars Thomas Seeberg; Cecilie Bendigtsen Schirmer; Anne Renolen; Elin Borgen; Bjørn Naume; Gro Wiedswang
Journal:  BMC Cancer       Date:  2020-11-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.